These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23640346)

  • 1. New treatment options for castration-resistant prostate cancer.
    Simondsen K; Kolesar J
    Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents for the management of castration-resistant prostate cancer.
    Cersosimo RJ
    Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment options for castrate-resistant prostate cancer: a urology perspective.
    Gomella LG; Gelpi F; Kelly WK
    Can J Urol; 2011 Aug; 18(4):5767-77. PubMed ID: 21854708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    Sartor O; Michels RM; Massard C; de Bono JS
    Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New agents in the arsenal to fight castrate-resistant prostate cancer.
    Ezzell EE; Chang KS; George BJ
    Curr Oncol Rep; 2013 Jun; 15(3):239-48. PubMed ID: 23440553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
    Gravanis I; Lopez AS; Hemmings RJ; Jiménez JC; Garcia-Carbonero R; Gallego IG; Giménez EV; O'Connor D; Giuliani R; Salmonson T; Pignatti F
    Oncologist; 2013; 18(9):1032-42. PubMed ID: 23966222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
    Vasani D; Josephson DY; Carmichael C; Sartor O; Pal SK
    Maturitas; 2011 Oct; 70(2):194-6. PubMed ID: 21831545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Castration-resistant prostate cancer: systemic therapy in 2012.
    Maluf FC; Smaletz O; Herchenhorn D
    Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
    Pal SK; Sartor O
    Maturitas; 2011 Feb; 68(2):103-5. PubMed ID: 21093995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Second line therapy for castration-resistant prostate cancer (CRPC)].
    Molitor B; Börgermann C
    Urologe A; 2012 Mar; 51(3):357-62. PubMed ID: 22113549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era for castrate resistant prostate cancer: a treatment review and update.
    Fong MK; Hare R; Jarkowski A
    J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.